Conformis, Inc. (CFMS): Price and Financial Metrics

Conformis, Inc. (CFMS): $2.76

0.28 (+11.29%)

POWR Rating

Component Grades













CFMS Stock Summary

  • With a one year PEG ratio of 0.04, CONFORMIS INC is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than only 0.64% of US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, CONFORMIS INC is reporting a growth rate of -732.98%; that's higher than only 2.39% of US stocks.
  • In terms of volatility of its share price, CFMS is more volatile than 98.85% of stocks we're observing.
  • Stocks that are quantitatively similar to CFMS, based on their financial statements, market capitalization, and price volatility, are MIND, WTT, NBRV, RWLK, and LFUS.
  • CFMS's SEC filings can be seen here. And to visit CONFORMIS INC's official web site, go to

CFMS Valuation Summary

  • In comparison to the median Healthcare stock, CFMS's EV/EBIT ratio is 96.51% lower, now standing at 0.3.
  • Over the past 90 months, CFMS's price/sales ratio has gone down 14.1.

Below are key valuation metrics over time for CFMS.

Stock Date P/S P/B P/E EV/EBIT
CFMS 2022-11-25 0.3 0.3 -0.3 0.3
CFMS 2022-11-23 0.3 0.3 -0.2 0.3
CFMS 2022-11-22 0.2 0.2 -0.2 0.3
CFMS 2022-11-21 0.3 0.3 -0.3 0.2
CFMS 2022-11-18 0.3 0.3 -0.2 0.3
CFMS 2022-11-17 0.2 0.2 -0.2 0.3

CFMS Growth Metrics

    Its 2 year net income to common stockholders growth rate is now at 77.06%.
  • Its 3 year price growth rate is now at -80.36%.
  • Its 5 year cash and equivalents growth rate is now at -41.48%.
Over the past 33 months, CFMS's revenue has gone down $17,375,000.

The table below shows CFMS's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 60.054 -32.811 -62.733
2022-06-30 60.523 -31.07 -60.504
2022-03-31 101.576 -16.984 -6.938
2021-12-31 99.86 -8.399 -2.413
2021-09-30 101.133 -18.417 6.941
2021-06-30 103.001 -10.064 13.731

CFMS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CFMS has a Quality Grade of B, ranking ahead of 76.62% of graded US stocks.
  • CFMS's asset turnover comes in at 0.884 -- ranking 27th of 186 Medical Equipment stocks.
  • CLPT, ANGO, and IVC are the stocks whose asset turnover ratios are most correlated with CFMS.

The table below shows CFMS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.884 0.672 0.319
2021-03-31 0.724 0.494 -0.538
2020-12-31 0.973 0.490 -0.465
2020-09-30 1.015 0.494 -0.415
2020-06-30 1.057 0.486 -0.449
2020-03-31 1.068 0.466 -0.503

CFMS Price Target

For more insight on analysts targets of CFMS, see our CFMS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $2.33 Average Broker Recommendation 1.5 (Moderate Buy)

CFMS Stock Price Chart Interactive Chart >

Price chart for CFMS

CFMS Price/Volume Stats

Current price $2.76 52-week high $23.57
Prev. close $2.48 52-week low $1.20
Day low $2.43 Volume 92,201
Day high $2.77 Avg. volume 47,968
50-day MA $3.35 Dividend yield N/A
200-day MA $9.02 Market Cap 20.75M

Conformis, Inc. (CFMS) Company Bio

ConforMIS is a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants that are individually sized and shaped, or customized, to fit each patient's unique anatomy. The company was founded in 2004 and is based in Bedford, Massachusetts.

CFMS Latest News Stream

Event/Time News Detail
Loading, please wait...

CFMS Latest Social Stream

Loading social stream, please wait...

View Full CFMS Social Stream

Latest CFMS News From Around the Web

Below are the latest news stories about CONFORMIS INC that investors may wish to consider to help them evaluate CFMS as an investment opportunity.

Conformis Announces First Procedure Performed Using New Actera™ Hip System

First Actera™ procedure underscores company’s ongoing commitment to advancing joint replacement technology by leveraging its data-driven approach and surgical planning expertiseBILLERICA, Mass., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a leading medical device company that features personalized knee and hip replacement products, today announced that the first procedure with the company’s new Actera™ Hip System has been performed. Dr. William Kurtz, MD performed the hip re

Yahoo | November 29, 2022

Conformis Announces Full Commercial Launch of Imprint™

Conformis’ Imprint™ knee system introduces the new “Made-to-Measure” product category option for Total Knee Arthroplasty (TKA)BILLERICA, Mass., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a leading medical technology company featuring personalized knee and hip replacement products, today announced the full commercial launch of its new Imprint™ knee system. This launch marks the formal transition to its new U.S. business model where the made-to-measure Imprint™ system is now

Yahoo | November 17, 2022

Conformis, Inc. Announces Settlement of Medacta Patent Litigation

Conformis Settles Medacta Litigation Related to Patient-Specific InstrumentsBILLERICA, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that it has entered into a settlement and license agreement with Medacta USA, Medacta Germany GmbH, and Medacta International SA (together, “Medacta”) that resolves all patent disputes between the companies. “We are pleased to have resolved all of the ongoing patent litigation related to the Medacta dispute,” said Mark Augus

Yahoo | November 14, 2022

Conformis, Inc.'s (NASDAQ:CFMS) 48% loss last week hit both individual investors who own 52% as well as institutions

A look at the shareholders of Conformis, Inc. ( NASDAQ:CFMS ) can tell us which group is most powerful. The group...

Yahoo | November 11, 2022

Conformis, Inc. Effects 1-for-25 Reverse Stock Split

BILLERICA, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) (“Conformis”) announced that it will effect a 1-for-25 reverse stock split at 5:00 p.m. Eastern time today. Beginning with the opening of trading on November 10, 2022, Conformis’ common stock will trade on the Nasdaq Capital Market on a split-adjusted basis under a new CUSIP number 20717E200. At Conformis’ Special Meeting of Stockholders on October 26, 2022, Conformis’ stockholders approved the proposal to authoriz

Yahoo | November 9, 2022

Read More 'CFMS' Stories Here

CFMS Price Returns

1-mo -18.22%
3-mo -57.54%
6-mo -73.63%
1-year -86.76%
3-year -94.06%
5-year -96.34%
YTD -85.50%
2021 15.36%
2020 -56.00%
2019 316.67%
2018 -84.87%
2017 -70.62%

Continue Researching CFMS

Here are a few links from around the web to help you further your research on Conformis Inc's stock as an investment opportunity:

Conformis Inc (CFMS) Stock Price | Nasdaq
Conformis Inc (CFMS) Stock Quote, History and News - Yahoo Finance
Conformis Inc (CFMS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7072 seconds.